{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:12:39Z","timestamp":1761894759846},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T00:00:00Z","timestamp":1218499200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s12185-008-0150-z","type":"journal-article","created":{"date-parts":[[2008,8,11]],"date-time":"2008-08-11T03:29:16Z","timestamp":1218425356000},"page":"331-335","source":"Crossref","is-referenced-by-count":10,"title":["Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions"],"prefix":"10.1007","volume":"88","author":[{"given":"Makoto","family":"Yoshimitsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiichiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kakushi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomichi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuwa","family":"Tei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,12]]},"reference":[{"key":"150_CR1","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood.V79.11.3067.3067","volume":"79","author":"AJ Barrett","year":"1992","unstructured":"Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992;79:3067\u201370.","journal-title":"Blood"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"150_CR3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965\u201371.","journal-title":"Blood"},{"key":"150_CR4","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2003-01-0154","volume":"103","author":"B Wassmann","year":"2004","unstructured":"Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph\u00a0+\u00a0ALL) treated with imatinib. Blood. 2004;103:1495\u20138.","journal-title":"Blood"},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038\u201342.","journal-title":"N Engl J Med"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","volume":"15","author":"RH Collins Jr","year":"1997","unstructured":"Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433\u201344.","journal-title":"J Clin Oncol"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","volume":"104","author":"M Towatari","year":"2004","unstructured":"Towatari M, Yanada M, Usui N, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004;104:3507\u201312.","journal-title":"Blood"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876\u201380.","journal-title":"Science"},{"key":"150_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031\u20137.","journal-title":"N Engl J Med"},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645\u201352.","journal-title":"N Engl J Med"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460\u20136.","journal-title":"J Clin Oncol"},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","volume":"106","author":"B Wassmann","year":"2005","unstructured":"Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD\u00a0+\u00a0Philadelphia-positive acute lymphoblastic leukemia (Ph\u00a0+\u00a0ALL). Blood. 2005;106:458\u201363.","journal-title":"Blood"},{"key":"150_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S1470-2045(05)70391-0","volume":"6","author":"BN Savani","year":"2005","unstructured":"Savani BN, Srinivasan R, Espinoza-Delgado I, et al. Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncol. 2005;6:809\u201312.","journal-title":"Lancet Oncol"},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435:1267\u201370.","journal-title":"Nature"},{"key":"150_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","volume":"41","author":"AW Loren","year":"2008","unstructured":"Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2008;41:483\u201393.","journal-title":"Bone Marrow Transplant"},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","volume":"111","author":"CI Chen","year":"2008","unstructured":"Chen CI, Maecker HT, Lee PP. Development and dynamics of robust T cell responses to CML under imatinib treatment. Blood. 2008;111:5342\u20139.","journal-title":"Blood"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1532\/IJH97.05086","volume":"82","author":"A Takami","year":"2005","unstructured":"Takami A, Okumura H, Yamazaki H, et al. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation. Int J Hematol. 2005;82:449\u201355.","journal-title":"Int J Hematol"},{"key":"150_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","volume":"101","author":"A Burchert","year":"2003","unstructured":"Burchert A, Wolfl S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101:259\u201364.","journal-title":"Blood"},{"key":"150_CR19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2003-12-4266","volume":"104","author":"AB Dietz","year":"2004","unstructured":"Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004;104:1094\u20139.","journal-title":"Blood"},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1158\/0008-5472.CAN-07-0302","volume":"67","author":"KM Brauer","year":"2007","unstructured":"Brauer KM, Werth D, von Schwarzenberg K, et al. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res. 2007;67:5489\u201397.","journal-title":"Cancer Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-008-0150-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0150-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T15:02:25Z","timestamp":1588863745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-008-0150-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,12]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s12185-008-0150-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,12]]}}}